Last reviewed · How we verify
Biguanide, DPP4 inhibitors, SGLT2 inhibitors
Biguanide, DPP4 inhibitors, SGLT2 inhibitors is a Small molecule drug developed by Metabolic Research Unit. It is currently in Phase 1 development.
At a glance
| Generic name | Biguanide, DPP4 inhibitors, SGLT2 inhibitors |
|---|---|
| Sponsor | Metabolic Research Unit |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biguanide, DPP4 inhibitors, SGLT2 inhibitors CI brief — competitive landscape report
- Biguanide, DPP4 inhibitors, SGLT2 inhibitors updates RSS · CI watch RSS
- Metabolic Research Unit portfolio CI
Frequently asked questions about Biguanide, DPP4 inhibitors, SGLT2 inhibitors
What is Biguanide, DPP4 inhibitors, SGLT2 inhibitors?
Biguanide, DPP4 inhibitors, SGLT2 inhibitors is a Small molecule drug developed by Metabolic Research Unit.
Who makes Biguanide, DPP4 inhibitors, SGLT2 inhibitors?
Biguanide, DPP4 inhibitors, SGLT2 inhibitors is developed by Metabolic Research Unit (see full Metabolic Research Unit pipeline at /company/metabolic-research-unit).
What development phase is Biguanide, DPP4 inhibitors, SGLT2 inhibitors in?
Biguanide, DPP4 inhibitors, SGLT2 inhibitors is in Phase 1.